Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot2 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions
: CTIS2024-516402-32-00 Primary Outcome 1 - TTL Representation
Raw ttl | Download
@prefix fhir: <http://hl7.org/fhir/> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
a fhir:EvidenceVariable ;
fhir:nodeRole fhir:treeRoot ;
fhir:id [ fhir:v "346487"] ;
fhir:meta [
fhir:versionId [ fhir:v "2" ] ;
fhir:lastUpdated [ fhir:v "2025-03-05T19:33:28.216Z"^^xsd:dateTime ]
] ;
fhir:text [
fhir:status [ fhir:v "generated" ] ;
fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p class=\"res-header-id\"><b>Generated Narrative: EvidenceVariable 346487</b></p><a name=\"346487\"> </a><a name=\"hc346487\"> </a><a name=\"346487-en-US\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">version: 2; Last updated: 2025-03-05 19:33:28+0000</p></div><p><b>url</b>: <a href=\"EvidenceVariable-346487.html\">EvidenceVariable CTIS2024-516402-32-00 Primary Outcome 1</a></p><p><b>identifier</b>: FEvIR Object Identifier/https://fevir.net/FOI/346487, FEvIR Linking Identifier/CTIS2024-516402-32-00 Primary Outcome 1, CTIS endPoint id/441508, <a href=\"http://terminology.hl7.org/6.2.0/NamingSystem-uri.html\" title=\"As defined by RFC 3986 (http://www.ietf.org/rfc/rfc3986.txt)(with many schemes defined in many RFCs). For OIDs and UUIDs, use the URN form (urn:oid:(note: lowercase) and urn:uuid:). See http://www.ietf.org/rfc/rfc3001.txt and http://www.ietf.org/rfc/rfc4122.txt \r\n\r\nThis oid is used as an identifier II.root to indicate the the extension is an absolute URI (technically, an IRI). Typically, this is used for OIDs and GUIDs. Note that when this OID is used with OIDs and GUIDs, the II.extension should start with urn:oid or urn:uuid: \r\n\r\nNote that this OID is created to aid with interconversion between CDA and FHIR - FHIR uses urn:ietf:rfc:3986 as equivalent to this OID. URIs as identifiers appear more commonly in FHIR.\r\n\r\nThis OID may also be used in CD.codeSystem.\">Uniform Resource Identifier (URI)</a>/urn:oid:2.16.840.1.113883.4.642.40.44.24.4</p><p><b>version</b>: 1.0.0-ballot2</p><p><b>name</b>: CTIS2024_516402_32_00_Primary_Outcome_1</p><p><b>title</b>: CTIS2024-516402-32-00 Primary Outcome 1</p><p><b>status</b>: Active</p><p><b>date</b>: 2025-03-27 17:53:24+0000</p><p><b>publisher</b>: HL7 International / Clinical Decision Support</p><p><b>contact</b>: HL7 International / Clinical Decision Support: <a href=\"http://www.hl7.org/Special/committees/dss\">http://www.hl7.org/Special/committees/dss</a></p><p><b>description</b>: </p><div><p>Response to therapy, defined by the absence of any of the following events: i) at 6-month follow-up: persistent renal replacement therapy, eGFR<15ml/mn/1,73m2, or patient death; ii) at W2 : persistent hemolysis despite well conducted antihypertensive therapy. Any Eculizumab rescue in the control group will be considered as a failure.</p>\n</div><p><b>copyright</b>: </p><div><p>https://creativecommons.org/licenses/by-nc-sa/4.0/</p>\n</div><p><b>author</b>: Brian S. Alper, MD, MSPH: </p></div>"^^rdf:XMLLiteral
] ;
fhir:url [ fhir:v "https://fevir.net/resources/EvidenceVariable/346487"^^xsd:anyURI] ;
fhir:identifier ( [
fhir:type [
( fhir:coding [
fhir:system [ fhir:v "http://terminology.hl7.org/CodeSystem/v2-0203"^^xsd:anyURI ] ;
fhir:code [ fhir:v "ACSN" ] ;
fhir:display [ fhir:v "Accession ID" ] ] ) ;
fhir:text [ fhir:v "FEvIR Object Identifier" ] ] ;
fhir:system [ fhir:v "urn:ietf:rfc:3986"^^xsd:anyURI ] ;
fhir:value [ fhir:v "https://fevir.net/FOI/346487" ] ;
fhir:assigner [
fhir:display [ fhir:v "Computable Publishing LLC" ] ]
] [
fhir:type [
fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ;
fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ] ;
fhir:value [ fhir:v "CTIS2024-516402-32-00 Primary Outcome 1" ] ;
fhir:assigner [
fhir:display [ fhir:v "Computable Publishing LLC" ] ]
] [
fhir:type [
fhir:text [ fhir:v "CTIS endPoint id" ] ] ;
fhir:value [ fhir:v "441508" ]
] [
fhir:system [ fhir:v "urn:ietf:rfc:3986"^^xsd:anyURI ] ;
fhir:value [ fhir:v "urn:oid:2.16.840.1.113883.4.642.40.44.24.4" ]
] ) ;
fhir:version [ fhir:v "1.0.0-ballot2"] ;
fhir:name [ fhir:v "CTIS2024_516402_32_00_Primary_Outcome_1"] ;
fhir:title [ fhir:v "CTIS2024-516402-32-00 Primary Outcome 1"] ;
fhir:status [ fhir:v "active"] ;
fhir:date [ fhir:v "2025-03-27T17:53:24+00:00"^^xsd:dateTime] ;
fhir:publisher [ fhir:v "HL7 International / Clinical Decision Support"] ;
fhir:contact ( [
fhir:name [ fhir:v "HL7 International / Clinical Decision Support" ] ;
( fhir:telecom [
fhir:system [ fhir:v "url" ] ;
fhir:value [ fhir:v "http://www.hl7.org/Special/committees/dss" ] ] )
] ) ;
fhir:description [ fhir:v "Response to therapy, defined by the absence of any of the following events: i) at 6-month follow-up: persistent renal replacement therapy, eGFR<15ml/mn/1,73m2, or patient death; ii) at W2 : persistent hemolysis despite well conducted antihypertensive therapy. Any Eculizumab rescue in the control group will be considered as a failure."] ;
fhir:copyright [ fhir:v "https://creativecommons.org/licenses/by-nc-sa/4.0/"] ;
fhir:author ( [
fhir:name [ fhir:v "Brian S. Alper, MD, MSPH" ]
] ) .
|
Propose a change